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Papillomaviruses (PVs) bind in a specific and saturable fashion to a range of epithelial and other cell lines.
Treatment of cells with trypsin markedly reduces their ability to bind virus particles, suggesting that binding
is mediated via a cell membrane protein. We have investigated the interaction of human PV type 6b L1
virus-like particles (VLPs) with two epithelial cell lines, CV-1 and HaCaT, which bind VLPs, and a B-cell line
(DG75) previously shown not to bind VLPs. Immunoprecipitation of a mixture of PV VLPs with [35S]methi-
onine-labeled cell extracts and with biotin-labeled cell surface proteins identified four proteins from CV-1 and
HaCaT cells of 220, 120, 87, and 35 kDa that reacted with VLPs and were not present in DG75 cells. The a6b4
integrin complex has subunits corresponding to the VLP precipitated proteins, and the tissue distribution of
this complex suggested that it was a candidate human PV receptor. Monoclonal antibodies (MAbs) to the a6
or b4 integrin subunits precipitated VLPs from a mixture of CV-1 cell proteins and VLPs, whereas MAbs to
other integrin subunits did not. An a6 integrin-specific MAb (GoH3) inhibited VLP binding to CV-1 and
HaCaT cells, whereas an anti-b4 integrin MAb and a range of integrin-specific and other MAbs did not.
Furthermore, human laminin, the natural ligand for the a6b4 integrin, was able to block VLP binding. By use
of sections of monkey esophagus, the distribution of a6 integrin expression in the basal epithelium was shown
to coincide with the distribution of bound VLPs. Taken together, these data suggest that VLPs bind specifically
to the a6 integrin subunit and that integrin complexes containing a6 integrin complexed with either b1 or b4
integrins may act as a receptor for PV binding and entry into epithelial cells.
Human papillomaviruses (HPVs) are recognized as the eti-
ological agents for skin, plantar, genital, and laryngopharyn-
geal warts, and infection with some genital genotypes of HPV
is a major risk factor for the development of anogenital cancer
(3, 40). The inability to propagate PV in vitro has hampered
definition of the early phases of PV infection. PV infects skin
and mucosal surfaces, and this restricted cell tropism is thought
to be mediated by PV interaction with host cell factors. The
first step in infection with a crystalline virus is generally attach-
ment of the virus to a specific receptor on the surface of a
susceptible host cell. The receptor molecule on the cell surface
can be a protein (usually a glycoprotein) or a carbohydrate
structure localized on glycoproteins or glycolipids. For most
viruses, attachment to cell membranes via an interaction with
cell surface proteins is the primary determinant of tropism
(12), and many viral receptors are now well characterized.
Echoviruses 1 and 8 use the integrin a2b1 (VLA-2) (1); the
avb3/a5 integrins function as a secondary receptor for adeno-
virus (36); cytomegalovirus (24) and simian virus 40 (4) bind to
major histocompatibility complex (MHC) class I proteins; and
human immunodeficiency virus binds to CD4 via gp120 (7).
However, the nature of any putative cellular receptor for PV
has yet to be elucidated.
The PV capsid consists of two virally encoded proteins, L1
and L2, which migrate in sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis (SDS-PAGE) at 55 and 75 kDa, respec-
tively (9, 19). The L1 protein is the major capsid protein and
when expressed in various eukaryotic expression systems is
able to self-assemble into virus-like particles (VLPs) (15, 28,
34, 39). The L2 protein appears to be involved in DNA binding
and encapsidation (38). VLPs have been used to characterize
PV binding to cells by various techniques, and we and others
have shown that PV particles bind to an unknown receptor
present in a variety of different cell types (21, 25, 26, 35). VLP
binding is trypsin sensitive, suggesting that the putative recep-
tor is a protein, and binding has been shown to be saturable
with 1 3 104 to 2 3 104 receptors/cell (25, 35). Soluble L1
protein not configured as VLPs also binds to cells but in a
trypsin-insensitive and nonsaturable manner (25). VLPs com-
posed of either L1 alone or L1 and L2 have been shown to be
equally effective in binding to cells (26). VLPs bind to a wide
range of cell types, but the highest degree of binding per cell
occurs with epithelial and mesenchymal cells. Together, these
data suggest that any putative receptor is a conserved and
widely expressed molecule.
It has previously been shown that a human B lymphoma cell
line (DG75) did not bind VLPs (25). We now demonstrate that
four VLP-binding proteins of 220, 120, 87, and 35 kDa are
found in two cell lines that bind VLPs but not in DG75 cells.
As two of these proteins possessed the same mass as the a6b4
integrin complex (220 and 120 kDa), this complex was inves-
tigated as a potential receptor candidate.
MATERIALS AND METHODS
VLPs, cell lines, and antibodies. HPV type 6b (HPV6b) L1 VLPs were pro-
duced in SF9 cells by using HPV6b L1 recombinant baculovirus, purified, quan-
titated, and examined by electron microscopy as previously described (25). CV-1
African green monkey kidney epithelial cells were obtained from the American
Type Culture Collection (catalog no. CCL70); HaCaT human epithelial cells
were a gift from Norbert Fusenig, Deutsches Krebsforschungszentrum, Heidel-
berg, Germany; and DG75, a Burkitt’s lymphoma line, was a gift of Ihor Misko,
Queensland Institute of Medical Research, Brisbane, Queensland, Australia.
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Monoclonal antibodies (MAbs) 8 and 39, raised to HPV16 L1, which cross-react
with HPV6b L1, were a gift of Stephen Kelsall, Department of Microbiology,
University of Western Australia. The following MAbs to integrins were pur-
chased: anti-integrin a6 intracytoplasmic domain (4E9G8; Immunotech, Mar-
seille, France), anti-integrin a6 extracellular domain (GoH3; Serotec Ltd., Ox-
ford, England), and anti-b4 integrin (3E1; Gibco-BRL). Anti-av (P3G8), anti-
avb5 (P5H9-E11), anti-a2 (P1E6), anti-a4 (P4G9-E11), anti-b1 (P5D2), and
anti-b2 (P4H9-A11) integrin antibodies were a kind gift from Elizabeth Wagner,
University of Minnesota. An HPV6b L1 VLP-specific rabbit polyclonal anti-
serum, raised by immunizing a rabbit with purified HPV6b L1 VLPs three times
without adjuvant, was a gift of Shi Wen Peng, Centre for Immunology and
Cancer Research (CICR), Brisbane, Queensland, Australia. This antiserum rec-
ognizes native but not denatured VLPs by enzyme-linked immunosorbent cap-
ture assay. Horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rab-
bit immunoglobulin (Ig) antisera were purchased from Silenus (Hawthorne,
Australia), and fluorescein isothiocyanate (FITC)-conjugated anti-mouse and
anti-rabbit Ig antisera were purchased from Sigma (Raritan, N.J.) and Rockland
(Gilbertsville, Pa.). The CD34-specific MAb BI-3C5 was a gift from Robert
Tindle, CICR, Brisbane, Queensland, Australia, and the MHC class I MAb was
from Serotec. Mouse laminin (Boehringer Mannheim), human vitronectin (Sig-
ma), and RGD motif peptides (GRGDSP and GRGESP) (Life Technologies,
Gaithersburg, Md.) were used as purchased. Human laminin was purchased from
Life Technologies.
[35S]methionine labeling of cells. Cells (2 3 107) were washed twice in me-
thionine-free RPMI (CSL Ltd., Melbourne, Victoria, Australia) and incubated in
the same medium for 30 min at 378C. The cells were labeled with [35S]methi-
onine (100 mCi/ml; Amersham) for 3 h, washed twice with ice-cold 0.15 M
phosphate-buffered 0.9% saline (PBS) (pH 7.4), scraped off, and resuspended in
homogenization buffer (100 mM HEPES [pH 7.9], 20 mM MgCl2, 200 mM
CaCl2, 100 mM NaF, 200 mM phenylmethylsulfonyl fluoride, and 100 mg of
aprotinin per ml). The cells were lysed on ice with 300 strokes of a Dounce
homogenizer.
Biotinylation of VLPs and cell surface proteins. VLPs were biotinylated at a
molar ratio of 1,000:1 with Immuno Sulfo-NHS-biotin (Pierce, Rockford, Ill.).
VLPs (20 mg) were mixed with biotin so that the final biotin concentration was
500 ng/ml and held at room temperature for 4 h. Biotin was then removed either
by centrifugation through Centricon microconcentrators (Amicon) or by dialysis
against PBS overnight. Cell surface proteins were biotinylated by washing 5 3
107 cells three times in ice-cold PBS containing 0.1 mM CaCl2–1 mM MgCl2
(PBS-CaMg). N-Hydroxysulfosuccinimide (NHS)-biotin (sulfosuccinimidobi-
otin) was added to a final concentration of 200 mg/ml in PBS-CaMg, and the cells
were held for 30 min at 48C. The biotin solution was removed, fresh biotin
solution was added, and the cells were held for a further 30 min at 48C. The cells
were washed once with PBS containing 0.1 M glycine and four times with PBS
before being harvested by centrifugation or scraping.
Immunoprecipitations. Cell extracts were prepared by lysis of cells in RIPA
buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10
mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.14 mg of aprotinin per ml,
Tris-HCl; pH 7.5) followed by brief sonication. Extracts were clarified by cen-
trifugation and pretreated with anti-VLP antibody and protein A-Sepharose
(Pharmacia, Uppsala, Sweden) for 60 min at 48C to remove cross-reacting pro-
teins. Cell extract (70 mg) was made up to 500 ml in PBS before the addition of
5 mg of VLPs, and the mixture was held at 48C for 60 min. Anti-VLP antibodies
were added, and the mixture was held at 48C for 30 min. Protein A-Sepharose,
which had previously been blocked in 5% skim milk–1% bovine serum albumin
in PBS, was added, and the mixture was held at 48C for a further 30 min.
Complexes were washed five times at 48C with 0.5 ml of PBS before the addition
of SDS-PAGE loading buffer. Samples were boiled for 5 min, briefly centrifuged,
and subjected to SDS-PAGE.
Flow cytometry. Analysis of expression of cell surface molecules by flow cy-
tometry was performed as described previously (25).
VLP binding assays. HaCaT or CV-1 cells (105) were grown to confluence as
adherent monolayers, detached by using 0.25% trypsin–0.02% EDTA, and then
held in suspension for 2 h at 378C with occasional swirling as described previously
(25). Before analysis of binding, cells were first washed twice with Dulbecco
modified Eagle medium plus 0.2% bovine serum albumin (binding medium) and
then held in binding medium for 1 h on ice, in a total volume of 200 ml, with
added antibodies or receptor ligands as indicated. The cells were then washed
twice with binding medium by being spun for 20 s at 9,500 3 g. VLPs (50 to 150
ng, suspended in binding medium) were added to the cells, which were held on
ice for 90 min. The cells were extensively washed with PBS, resuspended in
SDS-PAGE loading buffer, boiled for 10 min, and loaded onto an SDS-poly-
acrylamide gel. For studies of neutralization of HPV6b VLPs, VLPs were mixed
with a 1:12 dilution of a rabbit polyclonal anti-HPV6b VLP antibody in binding
medium for 1 h at 228C and then added to cells.
Immunoblotting. Proteins separated by SDS-PAGE (10% resolving gel, 4.5%
stacking gel, 60 min at 100 V) were electrically transferred (80 min at 200 V) to
nitrocellulose filters (Amersham) and held in PBS–0.05% Tween 20 plus 5%
milk powder for 1 h at 228C. Antibodies were added, and the filter was held for
1 h at 228C. After three washes with PBS plus 0.05% Tween 20, bound antibody
was visualized by incubation with HRP-conjugated anti-species antiserum for 1 h
at 228C, followed by three washes as described above and HRP detection by
enhanced chemiluminescence (ECL) (Amersham) according to the manufactur-
er’s instructions. The intensity of immunoblot bands was assessed with a Molec-
ular Dynamics Personal Densitometer.
Immunofluorescence. Monkey esophageal skin sections (Inova, San Diego,
Calif.) were exposed to VLPs suspended at 50 ng/ml in PBS for 60 min at 228C
and washed twice in PBS. The slides were then exposed to a conformational
anti-VLP rabbit antiserum (or an anti-integrin antibody), washed, and held for a
further 60 min at room temperature with an appropriate FITC-conjugated an-
ti-Ig antibody before detection by epifluorescence microscopy, using appropriate
filter combinations for FITC.
RESULTS
Characterization of HPV VLP receptor-negative and -posi-
tive cell lines. It has previously been shown that HPV6b L1
VLPs bind to a range of cell lines in a specific, saturable
manner. A monkey epithelial cell line, CV-1, was shown to
bind the most VLPs per cell of the cell lines tested, while a
human B-cell line, DG75, was unable to bind VLPs (25). To
increase the sensitivity of our VLP binding assay, we modified
the previously used assay, in which VLP binding was detected
by flow cytometry, to allow detection of VLP binding by im-
munoblotting with an L1-specific MAb. SDS-PAGE-separated
extracts of cells exposed to VLPs were probed with the MAb,
and VLP binding was quantitated by densitometry. When VLP
binding was assayed by using a monolayer cell culture, some
assay conditions promoted cell detachment, so assays were
routinely performed using cells in suspension culture. Where
assay conditions permitted comparison, the same results could
be obtained for cells grown in suspension and in monolayers
(data not shown).
Using this modified VLP binding assay, we confirmed the
observation from the flow cytometry-based assay that HPV6b
L1 VLPs bound to CV-1 cells, whereas binding to DG75 cells
was minimal (Fig. 1). We observed that the human epithelial
cell line HaCaT bound similar amounts per cell of HPV6b
VLPs to CV-1 cells. Binding of VLPs to CV-1 and many other
cell types is prevented by pretreatment of the cells with trypsin
(21, 25), suggesting that a membrane protein is involved in
VLP binding to cells. We therefore examined whether binding
of VLPs to HaCaT cells was trypsin sensitive (Fig. 1) and
observed, using the modified VLP binding assay, that trypsin
treatment of HaCaT cells prior to exposure to VLPs reduced
FIG. 1. Binding of HPV6b L1 VLPs to cells detected by immunoblotting for
L1 protein using L1-specific MAb. HaCaT and DG75 cells were treated with
trypsin and exposed to VLPs as indicated (1, treatment; 2, no treatment) and
washed extensively. The cells were then lysed, and the lysate was separated by
SDS-PAGE and transferred to nitrocellulose, which was exposed to L1 MAb 39.
Bound antibody was detected by use of HRP-conjugated antiserum to mouse
IgG followed by ECL. The major immunoreactive L1 band has an apparent
molecular mass of 55 kDa.
2450 EVANDER ET AL. J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
binding of VLPs by 90%, in agreement with the estimate of
88% reduction from flow cytometry analysis. The binding of
VLPs to trypsin-treated HaCaT cells and the minimal binding
of VLPs to DG75 cells observed in the more sensitive assay
used here are likely to represent binding of denatured L1
molecules, which adhere nonspecifically to cells (25): approx-
imately 10% of our VLP preparation has an elution profile on
size exclusion gel chromatography consistent with monomeric,
presumably denatured, L1 protein. Having shown that CV-1
and HaCaT cells bind VLPs similarly, and having confirmed in
a more sensitive assay that DG75 cells did not bind a significant
amount of VLPs at a concentration (50 ng/ml) sufficient to
saturate the saturable binding of VLPs to CV-1 cells, we used
these three cell lines to identify the trypsin-sensitive membrane
proteins which mediate saturable binding of HPV6b L1 VLPs
to cells. Hereafter, such proteins are referred to as PV receptor
proteins.
Characterization of epithelial cell proteins that interact
with VLPs. Our first approach to identification of PV receptor
proteins was to enrich [35S]methionine-labeled total cell pro-
tein extracts for proteins which could bind to VLPs, using
coprecipitation. Cell extracts were exposed to HPV6b L1
VLPs, and receptor protein-VLP complexes were isolated by
immunoprecipitation with HPV16 L1-specific MAb 39, which
binds HPV6b L1 VLPs. Proteins with apparent molecular
masses of 120 and 220 kDa as determined by SDS-PAGE were
consistently enriched in immunoprecipitates from CV-1 cell
lysates mixed with HPV6b L1 VLPs (Fig. 2A), whereas no
proteins of similar size could be isolated from DG75 cell ly-
sates by the same technique.
To confirm and extend these initial findings and to increase
the probability of defining membrane-associated PV receptor
proteins, we labeled cell surfaces of CV-1 and DG75 cells with
NHS-biotin, solubilized the cell membrane with radioimmuno-
precipitation assay buffer and mixed the solubilized membrane
proteins with HPV6b VLPs. Proteins binding to VLPs were
identified by immunoprecipitation of the VLP-membrane pro-
tein mixture with L1-specific MAbs as before, followed by
analysis of the biotinylated proteins in the precipitate by SDS-
PAGE. While several cell surface proteins from both DG75
and CV-1 cells (Fig. 2B) were reactive, four biotinylated mem-
brane proteins were consistently identified in CV-1 cell ex-
tracts immunoprecipitated with an L1 MAb in the presence of
VLPs that were not identified when either DG75 extracts or
CV-1 extracts immunoprecipitated without addition of VLPs
were used. These proteins had apparent molecular masses of
220, 120, 87, and 35 kDa as determined by SDS-PAGE. Two
proteins (220 and 120 kDa) were of comparable size to the
proteins identified as candidate PV receptor proteins in
[35S]methionine-labeled protein extracts.
Distribution of the a6b4 integrin. The SWISS-PROT pro-
tein sequence database was searched for epithelial cell surface
proteins with apparent molecular masses corresponding to
those of the proteins apparently binding to VLPs. This search
indicated that the a6b4 integrin was a candidate receptor pro-
tein, as the a6 integrin subunit is a heterodimer of a 120- and
a 25-kDa protein, while the b4 subunit is a single protein of 220
kDa. Tissue distribution of the a6b4 integrin is limited to ep-
ithelial, endothelial, and neural cells (14, 30), which is consis-
tent with the distribution of cell types that show the highest
affinity for VLPs (25). We therefore investigated expression of
the a6b4 integrin on CV-1 and DG-75 cells by flow cytometry.
CV-1 cells expressed both a6 and b4 integrins as membrane
proteins, while DG75 cells expressed neither (Fig. 3). As ex-
pected, both cell types expressed the b1 integrin chain (a 130-
kDa protein that is able to bind to many a-integrin chains,
including a6).
Association of VLPs with integrin subunits. To determine
whether a6b4 integrin could associate with HPV VLPs, we
FIG. 2. Cellular proteins that bind to HPV6b L1 VLPs. (A) [35S]methionine-
labeled CV-1 and DG75 cell extracts were exposed to HPV6b L1 VLPs, and
VLP-binding proteins were immunoprecipitated as indicated. Precipitates were
separated by SDS-PAGE and analyzed by autoradiography. Lanes 1, no anti-
serum and no VLPs; lanes 2, anti-L1 MAb 39; lanes 3, as for lane 2 but with VLPs
added. Bands specific for CV-1 cells precipitated with L1 VLP-specific antiserum
are indicated (arrows). (B) DG75 and CV-1 cell surface proteins were biotin
labeled. Cell extracts were mixed with VLPs, and interacting proteins were
precipitated with a VLP-specific antiserum, separated by SDS-PAGE as for
panel A, and transferred to nitrocellulose. Biotinylated proteins were detected by
use of peroxidase-labeled streptavidin followed by ECL. Four bands (arrows) of
220, 120, 87, and 35 kDa were observed only in CV-1 lysates precipitated in the
presence of VLPs. 1 and 2, addition or no addition of VLPs, respectively.
Molecular masses (in kilodaltons) are shown on the left.
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performed coimmunoprecipitation experiments, using biotin-
ylated VLPs to facilitate detection of precipitated VLPs. We
first established that VLP biotinylation did not affect VLP
morphology or VLP binding to cells. As shown in Fig. 4, bio-
tinylated VLPs had a normal appearance under electron mi-
croscopy and were able to bind cells with an affinity equal to
that of nonbiotinylated VLPs. As further confirmation that
VLP biotinylation did not interfere with receptor interaction,
we established that binding of biotinylated VLPs to cells was
blocked by a polyvalent antibody recognizing conformational
epitopes of HPV6b VLPs and previously shown to block VLP
binding to epithelial cells (data not shown). Furthermore, bi-
otinylated VLPs were able to react with proteins of 220, 120,
87, and 35 kDa from CV-1 cell extracts labeled with [35S]me-
thionine (data not shown). Biotinylated VLPs were used in
coimmunoprecipitation experiments with CV-1 and HaCaT
membrane proteins as before. Precipitation of VLP-membrane
protein complexes was examined, using a range of MAbs spe-
cific for integrin proteins. Both a6-specific (Fig. 5, lane 6) and
b4-specific (Fig. 5, lane 9) MAbs precipitated a protein from
mixtures of VLPs and CV-1 membrane protein with the same
apparent molecular mass as a protein precipitated by an an-
ti-L1 MAb known to react with HPV6b VLPs (Fig. 5, lane 4).
This protein was not identified in unprecipitated VLP-mem-
brane protein mixtures (Fig. 5, lane 3) or in immunoprecipi-
tates obtained with MAbs specific for a range of other integrins
(anti-a2, -b1, -a4, and -b2) or for CD34, a cell membrane
protein present on DG75 but not CV-1 cells. All MAbs used
were precipitated effectively by protein A-Sepharose, as judged
by the quantity of immunoreactive mouse IgG within the im-
munoprecipitate (data not shown).
Antibodies to a6 integrin reduce VLP binding to cells. To
confirm a role for the a6 integrin chain in the binding of HPV
VLPs to cells, we determined whether VLP binding to cells
could be inhibited by pretreatment of the cells with integrin
chain-specific MAbs. For these assays, HaCaT cells, which
express the a6b4 integrin (16), were used. Pretreatment of
HaCaT cells with an a6-specific MAb, GoH3, reduced VLP
binding by an average of (63 6 6.3)% (Fig. 6B). Figure 6B
shows the averages from 10 separate experiments. An anti-b4
antibody reduced binding only slightly (18%). Other integrin
MAbs, specific for subunits b1, a2, av, and avb5, did not sig-
nificantly reduce VLP binding (15, 9, 13, and 5%, respectively),
nor did antibodies against MHC class I framework determi-
nants (4%) or CD34 (13%) (Fig. 6B). The same results were
observed with CV-1 cells as with HaCaT cells. No increase in
blocking of VLP binding over that observed with an a6-specific
MAb could be demonstrated if a combination of a6- and b4-
specific MAbs or of a6- and b1-specific MAbs was used. The
natural ligand for the a6b4 heterodimer is believed to be lami-
nin. Preincubation of cells with human laminin was able to
block binding of VLPs in a dose-dependent manner, with 250
ng having no effect upon binding while 500 ng resulted in
complete loss of binding (Fig. 6C). We looked for a reduction
of VLP binding to cells by pretreatment of cells with vitronec-
tin or with a polyclonal antiserum specific for the vitronectin
receptor (avb3/avb5), but no inhibition of binding was found in
either case. Additionally, no reduction in VLP binding was
FIG. 3. Analysis of the expression of a6, b1, and b4 integrins on CV-1 and DG75 cells by flow cytometry. In each panel, the black line corresponds to the histogram
of fluorescence intensities for cells exposed to secondary antibody only and the grey line indicates cells exposed additionally to the indicated primary antibody (top
panels, a6; middle panels, b1; bottom panels, b4).
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seen when cells were pretreated with an RGD peptide, which
has been demonstrated to inhibit binding of substrates to those
integrins which utilize the RGD binding motif, including avb3/
avb5.
FIG. 4. Biotinylated VLPs. Electron micrographs of normal (A) and biotin-
ylated (B) VLPs (magnifications, 360,000 and 380,000, respectively), showing
preservation of 55-nm empty PV-like structures; occasional tube forms are seen.
Bar, 100 nm. (C) Binding of VLPs to CV-1 cells, using an immunoblot assay for
L1 to detect bound VLPs (see Materials and Methods). Lane 1, no VLPs added;
lane 2, untreated VLPs; lane 3, biotin-labeled VLPs. In each case, the major
band at 55 kDa corresponds to L1 protein.
FIG. 5. Interaction between VLPs and integrins. Biotin-labeled VLPs were
mixed with digitonin-prepared cell lysates and incubated for 1 h. Immune com-
plexes were precipitated with antibodies (lanes 4 to 12) using protein A-Sepha-
rose. Immune complexes were analyzed by SDS-PAGE and transferred to nitro-
cellulose, and biotinylated L1 protein, corresponding to bound VLPs, was
detected with peroxidase-labeled streptavidin. Lane 1, biotin-labeled VLPs (pos-
itive control); lane 2, total cell extract (negative control); lane 3, no antibody;
lane 4, anti-L1 MAb; lane 5, no antibody; lane 6, anti-a6 (4E9G5); lane 7, anti-a2;
lane 8, anti-b1; lane 9, anti-b4; lane 10, anti-a4; lane 11, anti-b2; lane 12, anti-
CD34. The 80-kDa bands in lane 2 represent streptavidin binding activity in
unfractionated cell lysate. Molecular masses (in kilodaltons) are shown on the
left.
FIG. 6. Blocking of VLP binding to HaCaT cells by integrin antibodies and
laminin. (A) Assay as described for Fig. 1, with antibody added to the cells prior
to addition of VLPs as indicated below. Lane 1, no antibody; lane 2, anti-a6
(GoH3); lane 3, anti-b1; lane 4, anti-b4; lane 5, anti-a2; lane 6, cells only (no
VLPs added). (B) Reduction of VLP binding by anti-integrin antibodies. Assays
were done as for panel A, with binding quantitated by densitometry. Binding to
HaCaT cells not pretreated with antibody was arbitrarily assigned a value of
100%. Results for binding to cells treated with each antibody are calculated as a
percentage of the binding observed with untreated HaCaT cells and displayed as
percent blocking, defined as 100% 2 observed binding. (C) Blockage of VLP
binding by human laminin. VLP binding assays were performed as described
above, but cells were preincubated as described. Lane 1, cell-only control; lane 2,
no antibody; lane 3, anti-a6 (GoH3); lanes 4 and 5, human laminin (250 and 500
ng, respectively).
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In situ VLP binding to epithelial cells. Our data obtained
with cultured cell lines suggested that the a6 integrin subunit
might be a receptor for HPV VLPs. To investigate whether
HPV binding and a6 integrin expression occur on the same
cells in vivo, we examined binding of VLPs and distribution of
a6 integrin in monkey esophageal sections, as we had already
determined that a monkey epithelial cell line (CV-1) bound
VLPs. On monkey esophageal sections, VLPs bound to basal
and immediately suprabasal epithelial cells, and, in concur-
rence with the hypothesis that a6 is a component of a VLP
receptor, the distribution of staining for a6 integrin was similar
to the distribution of bound VLPs (Fig. 7A versus B). Intense
staining for a6 integrin was observed along the basal aspect of
cells along the basement membrane, with lighter staining of the
lateral side of basal cells and the first four or five layers of
suprabasal cells (Fig. 7B). As expected, b4 integrin staining was
limited to the basement membrane cells (Fig. 7D), while b1
integrin expression was distributed throughout the papillary
dermis, basement membrane, and first one or two layers of the
basal cells (Fig. 7C). All controls were negative for staining
(not shown).
DISCUSSION
Investigation of putative HPV receptors has been hampered
by a lack of in vitro replication systems for this virus. Produc-
tion of VLPs in eukaryotic expression systems using recombi-
nant DNA technology has allowed examination of the initial
steps in HPV infection. We show here, using a number of
different assays, that a6 integrin is able to interact with VLPs,
suggesting that it may function as a cellular receptor for PVs.
A protein with a mass similar to that of the a6 integrin subunit
copurifies from cell extracts with VLPs, antibodies to a6 inte-
grin can precipitate VLPs from a mixture of VLPs and cell
extract, a MAb against the a6 integrin subunit reduces binding
of VLPs to cells by 63%, and the distribution of expression of
a6 integrin in tissue sections matches the distribution of bound
VLPs. Furthermore, VLPs do not bind to the a6 integrin-
negative B-cell line DG75.
In our studies, a6-specific antibodies were able to block VLP
binding, whereas antibodies to a range of b integrins were
unable to block binding, suggesting that the b chains do not
play a key role in VLP interactions with integrins. The integrins
are heterodimeric glycoproteins comprising a and b subunits,
which are expressed in a variety of cell types. They are involved
primarily in cell-matrix and cell-cell interactions (13). The a6
subunit has a more limited tissue distribution than most inte-
grins and associates preferentially with the b4 subunit in epi-
thelial cells (14) and the b1 subunit in mesenchymal tissues
(30). The b4 subunit is known to form a heterodimer only with
the a6 subunit (13). Furthermore, a6 combines more efficiently
FIG. 7. Distribution of integrin expression and VLP binding in monkey esophageal mucosa. Frozen sections of esophagus were incubated with HPV6b L1 VLPs
and rabbit anti-VLP antiserum (A), anti-a6 MAb (B), anti-b1 MAb (C), and anti-b4 MAb (D). Binding of MAbs for panels B to D was detected with an FITC-labeled
anti-mouse IgG antibody. Control sections without primary antibody or without VLPs showed no staining. In each panel, the esophageal lumen is in the upper right.
Epifluorescence microscopy with a magnification of ca. 3300 was used.
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with b4 than with b1 (10), and in HaCaT cells as well as
primary human keratinocytes the a6 subunit is associated pri-
marily with b4 (16, 29). Our coprecipitation data show that
VLPs complex with both a6 and b4, whereas anti-b1 antibodies
were not able to precipitate VLPs from CV-1 cell extracts.
However, in HaCaT cells, the higher affinity of b4 for a6 leaves
no a6 available to pair with b1 (16), and this may be true also
for CV-1 cells, as the a6 integrin subunit associates preferen-
tially with the b4 subunit in epithelial and neuroepithelial cells
(14, 30). Mesenchyma-derived cells express a6b1 but not a6b4.
It has previously been observed that VLPs bind cells of mes-
enchymal origin (25) and also that at least two cell lines that
express a6b1 but not a6b4 were able to bind VLPs. Others have
shown that CHO cells, another cell line of mesenchymal origin,
can bind VLPs (26, 35). We therefore conclude that VLPs will
bind to a6 whether paired with b1 or b4. It remains to be
determined which complex has higher affinity for VLPs.
The a6 antibody (GoH3) used in our VLP binding assay did
not completely block VLP binding, even at a large molar excess
with respect to a6 complexes and VLPs. However, an average
reduction in binding of 63% compares favorably with figures
for other viruses that bind to integrins. For example, binding of
foot-and-mouth disease virus and coxsackievirus A9 is reduced
by 74 and 69%, respectively, by polyclonal antisera to the
avb3/b5 integrin (2). Approximately 10% of the observed bind-
ing of VLPs to both HaCaT and CV-1 cells in our assay is
trypsin insensitive and nonsaturable and may represent non-
specific binding of damaged or denatured VLPs. However, this
possible artifact would be insufficient to account for the ob-
served lack of quantitative binding inhibition, as we observed
an average of 63% inhibition of VLP binding to CV-1 and
HaCaT cells. This partial inhibition may be a property of the
GoH3 antibody, as this antibody inhibited a6 binding to ma-
trigel and laminin by 49 to 53% for primary human epidermal
keratinocytes (8) and by 70% for the choriocarcinoma cell line
JAR (11). Alternatively, there may be other receptors for
VLPs on epithelial cells, and we are pursuing further experi-
ments to address this question, as our studies revealed at least
two other cell surface proteins, of 87 and 35 kDa, which can
associate with VLPs. The anti-b4 MAb was devoid of any
blocking activity, but this does not completely rule out a role in
VLP binding, as the b4 integrin has a large extracellular do-
main and the antibody used may bind to a noncritical region.
The relative roles of b4 and b1 complexes in PV entry into cells
might be inferred by studying the nature of PV infection in
patients with hereditary deficiency of these proteins (22, 33).
The a6b4 integrin heterodimer is expressed exclusively in the
basal layer of cells of stratified squamous epithelium (6, 8, 14,
29), which is presumably the only site of productive PV infec-
tion, and a6b4 integrin expression is rapidly turned off at the
onset of cell differentiation (32). The a6b4 complex is an inte-
gral part of the hemidesmosome (29) and as a receptor for
laminins 1, 2, 4, and 5 (31) is involved in the interaction of
epithelial cells with the basement membrane. In support of the
role of the a6b4 complex being a receptor for PVs, human
laminin was able to block the binding of VLPs to HaCaT cells
in a dose-dependent manner. The a6 subunit is present over
the entire surfaces of basal cells and some cells in the imme-
diate suprabasal region, while the b4 subunit is localized to the
basal pole of basal cells (29). By contrast, b1 integrin subunit
expression is very weak on the basal aspect of basal epithelial
cells but stronger on all other surfaces of these cells: it pairs
with the a2 and a3 subunits in epithelial cells and is involved in
cell-cell adhesion (29). Our data show that expression of a6
integrin and binding of VLPs colocalize within the epithelium.
It is held that PVs infect basal epithelial cells and stimulate
their proliferation. Infection is believed to occur as a result of
exposure of basal cells to virus particles after minor trauma to
the epithelium. During wound healing, the a6b4 integrin be-
comes widely expressed over the entire surface of epithelial
cells as they migrate to cover the wound site (18). During this
process, a6b4 integrin is constitutively endocytosed and recy-
cled, with a rate of endocytosis of 1 to 2% of surface molecules
per min (5). Recycling of the receptor is believed to facilitate
cell migration, during which the integrin (which is attached to
the matrix) moves backwards on the cell as the cell advances.
Internalization of viruses together with integrins occurs with
another nonenveloped virus, adenovirus, which binds to avb3/
avb5 (36). We can therefore propose a model for PV infection
in which virus particles bind to the a6b4 integrin during wound
healing and are endocytosed during cell migration. a6b4 inte-
grin is believed to be attached to the microfilament network via
the hemidesmosome (10, 17, 31), and this may provide an
explanation for the observation that cytochalasin B inhibits PV
uptake in CV-1 cells (37), suggesting that PV particles endo-
cytosed together with a6b4 integrin may be transported to the
cell nucleus via a microfilament-dependent pathway. a6b4 in-
tegrin is also a signal transduction receptor (20, 23), and the
possibility that binding of PV to its receptor is able to induce
a state of altered viral permissiveness in the infected cell is
therefore raised.
Other viruses also enter cells after binding to integrins.
Echoviruses 1 and 8 bind to the integrin a2b2 (VLA-2) (1), the
avb3 integrin functions as a receptor for both coxsackievirus
A9 (27) and foot-and-mouth disease virus (2), and the avb3/b5
integrins function as a secondary receptor for adenovirus (36).
The a3b1 and avb3/b5 integrins recognize substrates that con-
tain RGD motifs, and peptides containing this sequence effec-
tively block viral binding. However, RGD-containing peptides
do not affect PV VLP binding, ruling out these integrins as
receptors.
Identification of the a6 integrin as a component of the cel-
lular receptor responsible for saturable binding of PVs to ep-
ithelial cells should allow studies of the mechanism of PV
particle uptake into cells, which may clarify whether the tro-
pism of PV for epithelial cells is due to the tissue specificity of
the receptor or uptake mechanisms. Targeting PVs to other
cell types through expression of the a6 molecule will facilitate
such studies. Identification of a receptor for PV particles
should lead to identification of residues on the PV particle that
are critical for PV binding and uptake and may allow a rational
approach to design of drugs to inhibit the process of PV in-
fection.
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